Lee Danner & Bass Inc. reduced its holdings in Pfizer (NYSE:PFE) by 3.7% in the 4th quarter, HoldingsChannel reports. The fund owned 165,584 shares of the biopharmaceutical company’s stock after selling 6,388 shares during the period. Lee Danner & Bass Inc.’s holdings in Pfizer were worth $5,997,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in PFE. Americafirst Capital Management LLC purchased a new stake in Pfizer in the 3rd quarter worth about $127,000. Delphi Private Advisors LLC lifted its stake in Pfizer by 84.3% in the 4th quarter. Delphi Private Advisors LLC now owns 3,499 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 1,600 shares in the last quarter. Lipe & Dalton lifted its stake in Pfizer by 6.9% in the 2nd quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock worth $155,000 after acquiring an additional 300 shares in the last quarter. Legacy Advisors LLC purchased a new stake in Pfizer in the 3rd quarter worth about $164,000. Finally, Oak Point Wealth Management purchased a new stake in Pfizer in the 4th quarter worth about $165,000. 71.19% of the stock is owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

A number of equities research analysts have recently weighed in on PFE shares. SunTrust Banks reaffirmed a “hold” rating and set a $40.00 price target (up from $33.00) on shares of Pfizer in a research note on Monday, January 29th. Jefferies Group set a $39.00 price target on Pfizer and gave the stock a “hold” rating in a research note on Monday, February 26th. Morningstar set a $38.00 price target on Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, January 30th. BMO Capital Markets set a $43.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, March 6th. Finally, Vetr downgraded Pfizer from a “buy” rating to a “hold” rating and set a $37.98 price target for the company. in a research note on Monday, January 15th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $39.20.

Shares of NYSE PFE opened at $36.53 on Tuesday. The company has a current ratio of 1.35, a quick ratio of 1.10 and a debt-to-equity ratio of 0.47. The stock has a market cap of $216,208.05, a PE ratio of 13.78, a P/E/G ratio of 1.82 and a beta of 0.90. Pfizer has a 52 week low of $31.67 and a 52 week high of $39.43.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating the Zacks’ consensus estimate of $0.56 by $0.06. The business had revenue of $13.70 billion for the quarter, compared to analyst estimates of $13.67 billion. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The firm’s revenue for the quarter was up .6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.47 EPS. research analysts expect that Pfizer will post 2.96 earnings per share for the current year.

Pfizer announced that its board has initiated a share buyback plan on Monday, December 18th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the biopharmaceutical company to reacquire shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company’s leadership believes its stock is undervalued.

In other news, EVP Rady A. Johnson sold 27,323 shares of the stock in a transaction dated Tuesday, March 13th. The stock was sold at an average price of $36.55, for a total transaction of $998,655.65. Following the transaction, the executive vice president now owns 70,332 shares of the company’s stock, valued at approximately $2,570,634.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director W Don Cornwell sold 1,758 shares of the stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $36.79, for a total value of $64,676.82. Following the transaction, the director now directly owns 1,000 shares in the company, valued at approximately $36,790. The disclosure for this sale can be found here. In the last three months, insiders have sold 248,037 shares of company stock worth $9,064,785. 0.06% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2018/04/17/pfizer-pfe-shares-sold-by-lee-danner-bass-inc.html.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.